Description
The ProbeSeq Glial Fibrillary Acidic Protein (GFAP) Nanobody is a recombinant single-domain antibody (VHH) engineered for high-affinity and selective binding to human GFAP, an intermediate filament protein released following astrocyte injury and central nervous system damage. This nanobody supports research-use diagnostic assay development, neuroinjury biomarker detection, and biosensor integration.
GFAP is a structural cytoskeletal protein expressed primarily in astrocytes and is widely recognized as a sensitive biomarker of traumatic brain injury, stroke, neuroinflammation, and neurodegenerative disease. Rapid and sensitive detection of GFAP is central to neurotrauma monitoring, disease progression studies, and development of point-of-care neurological diagnostics.
Derived from camelid heavy-chain antibody architecture, this nanobody consists of a single monomeric VHH domain (~15 kDa) providing high specificity, strong binding kinetics, and superior structural stability. Compared with conventional antibodies, nanobodies offer enhanced thermal stability, reduced steric hindrance, and efficient surface immobilization, making them ideal for electrochemical sensors, microfluidic platforms, and high-sensitivity assay systems.
Typical assay workflows use sample input volumes ranging from approximately 5–50 µL depending on platform configuration and detection method. The nanobody is compatible with serum, plasma, cerebrospinal fluid, cell lysates, and buffered biological samples following assay optimization.
What’s Included
Recombinant anti-GFAP single-domain VHH nanobody
Sequence and expression documentation for research traceability
Reconstitution and handling guidelines
Custom affinity tags (His-tag, biotin, Fc fusion), labeling options, and bulk production are available upon request.
Target Strategy
Engineered for high binding specificity to human GFAP protein epitopes
Minimal cross-reactivity with related cytoskeletal proteins
Stable performance under physiological conditions
Compatible with biosensor surface functionalization and immunoassay workflows
Product Format
Lyophilized format
Delivered dry for enhanced stability
Reconstitute in PBS or preferred buffer
Solution format
Supplied in PBS-based storage buffer
Typical concentration range 0.5–1 mg/mL
Tagged variants available upon request.
Performance Orientation
Electrochemical biosensors
Immunoassay development
Microfluidic and lab-on-chip systems
Surface immobilization workflows
Optical and fluorescence detection platforms
Point-of-care neurodiagnostic research devices
Quality Control
Sequence confirmation
Purity validation (SDS-PAGE / chromatography)
Binding verification testing
Concentration determination
Manufacturing quality review
Certificate of Analysis (CoA) available upon request.
Applications
Traumatic brain injury biomarker detection
Neuroinflammation and neurodegeneration research
Stroke and CNS injury studies
Immunoassay and biosensor development
Microfluidic diagnostic platform integration
Point-of-care neurological monitoring research
Storage
Store at –20 °C for long-term storage or 4 °C for short-term use.
Lyophilized nanobody stable for up to 12 months under recommended conditions. Avoid repeated freeze–thaw cycles.
